Eli Lilly And Co (LLY) Raised to “Buy” at ValuEngine

Eli Lilly And Co (NYSE:LLY) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Monday.

A number of other analysts also recently weighed in on LLY. JPMorgan Chase & Co. set a $100.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, June 11th. Credit Suisse Group boosted their target price on Eli Lilly And Co from $82.00 to $84.00 and gave the stock an “underperform” rating in a research report on Thursday, June 21st. DZ Bank restated a “hold” rating on shares of Eli Lilly And Co in a research report on Friday, June 22nd. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b” rating in a research report on Friday, June 29th. Finally, Cantor Fitzgerald set a $100.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, July 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $106.06.

Shares of LLY opened at $115.02 on Monday. The stock has a market cap of $115.25 billion, a PE ratio of 26.87, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $115.68.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. Eli Lilly And Co’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.11 EPS. On average, equities analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current year.

In related news, Director Jackson P. Tai acquired 2,168 shares of the stock in a transaction on Thursday, July 26th. The stock was purchased at an average price of $95.22 per share, for a total transaction of $206,436.96. Following the completion of the transaction, the director now owns 53,228 shares of the company’s stock, valued at approximately $5,068,370.16. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the sale, the insider now owns 3,530 shares of the company’s stock, valued at approximately $372,662.10. The disclosure for this sale can be found here. Insiders sold 1,770,943 shares of company stock valued at $178,470,135 in the last quarter. Corporate insiders own 0.11% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Pure Financial Advisors Inc. increased its stake in shares of Eli Lilly And Co by 18.3% during the third quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock valued at $340,000 after buying an additional 490 shares during the period. Mutual Advisors LLC increased its stake in shares of Eli Lilly And Co by 8.4% during the second quarter. Mutual Advisors LLC now owns 6,600 shares of the company’s stock valued at $563,000 after buying an additional 512 shares during the period. HL Financial Services LLC increased its stake in shares of Eli Lilly And Co by 0.6% during the second quarter. HL Financial Services LLC now owns 82,971 shares of the company’s stock valued at $7,080,000 after buying an additional 518 shares during the period. Waverton Investment Management Ltd increased its stake in shares of Eli Lilly And Co by 4.4% during the second quarter. Waverton Investment Management Ltd now owns 12,486 shares of the company’s stock valued at $1,065,000 after buying an additional 524 shares during the period. Finally, Busey Trust CO increased its stake in shares of Eli Lilly And Co by 2.3% during the second quarter. Busey Trust CO now owns 23,955 shares of the company’s stock valued at $2,044,000 after buying an additional 545 shares during the period. Hedge funds and other institutional investors own 76.56% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Stop Order

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply